Zealand Pharma pays Generate $30m upfront to design AI-built obesity protein drugs

Zealand Pharma has signed a collaboration with Generate Biomedicines to design new obesity and metabolic disease candidates using Generate's generative AI platform, paying $30 million upfront ¹. The deal was reported on 14 October 2026 ¹.

The terms

Generate stands to receive the $30 million upfront payment, a further $35 million in early preclinical milestones and up to $1.2 billion in potential later-stage payments, spread across two initial programmes ¹. Generate will run the early work through to the selection of lead candidates. Zealand then takes over clinical development, regulatory submissions and worldwide commercialisation ¹.

Zealand said the partnership takes it beyond small molecules and peptides into multispecific protein therapeutics, and extends the use of Generate's platform into cardiometabolic disorders ¹. Generate's chief executive, Mike Nally, said the two companies will "define what a great medicine for patients looks like for each of the two initial programmes", and then use the platform to design multispecific candidates that meet or exceed that profile ¹.

The two companies

Generate was incubated by Flagship Pioneering and uses AI to work out the three-dimensional structure of human proteins, including how they fold, to design new drugs ¹. It already has partnerships worth more than $1 billion each with Novartis and Amgen ¹. Earlier this year it raised $400 million in a Nasdaq IPO and put around $300 million of that towards its lead candidate GB-0895, a long-acting anti-TSLP antibody for severe asthma that current therapies do not adequately control ¹. Its pipeline also covers chronic obstructive pulmonary disease and cancer ¹.

Copenhagen-based Zealand has two obesity candidates in late-stage registration trials, both partnered: the amylin analogue petrelintide with Roche and the glucagon/GLP agonist survodutide with Boehringer Ingelheim ¹. Neither has yet produced clinical data suggesting it could displace the market leaders, Eli Lilly's Zepbound and Novo's Wegovy ¹.

What it means for the market

For investors in AI drug design, the structure is familiar: a small upfront payment, with almost all of the headline value tied to milestones that depend on candidates reaching later development ¹. Zealand joins Novartis and Amgen as a partner of Generate, which also runs its own clinical pipeline led by GB-0895 ¹.

For Zealand, the deal is a way to add a new drug format to an obesity portfolio whose most advanced assets are still unproven against Lilly and Novo ¹. It keeps the clinical and commercial rights, so the value it captures depends on its own ability to develop and sell the resulting medicines worldwide ¹.

For other obesity developers, the agreement shows a mid-sized challenger using an AI partner to move into multispecific proteins rather than competing only on peptides and small molecules ¹.

Caveats

The programmes are preclinical, and the milestones are potential payments rather than committed sums ¹. The deal covers two initial programmes and does not name targets ¹. The first payments due after signing are the early preclinical milestones worth $35 million, ahead of lead candidate selection by Generate ¹.